Efficacy

Xpovio (Selinexor) Efficacy in Treating Lymphoma

Xpovio (selinexor) is a prescription medicine that has been approved by the U.S. Food and Drug Administration (FDA) for use in certain types of lymphoma. Specifically, it is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. Selinexor functions as a selective inhibitor of nuclear export, working by blocking the export of tumor suppressor proteins, leading to their accumulation in the nucleus and the subsequent induction of apoptosis in cancer cells.

The efficacy of Xpovio in the treatment of DLBCL was evaluated in a multicenter, single-arm, open-label clinical trial. Patients who received Xpovio demonstrated a meaningful overall response rate (ORR), which is the proportion of patients who experienced a significant reduction in tumor burden. The median duration of response (DOR) for those who achieved a partial or complete response was also assessed, providing insight into the potential longevity of the treatment's effects. These results support the use of Xpovio in the specified patient population, offering a treatment option for those who have exhausted other therapies.

Epkinly (Epcoritamab-bysp) Efficacy in Treating Lymphoma

Epkinly (epcoritamab-bysp) is an investigational bispecific antibody designed for the treatment of certain B-cell non-Hodgkin lymphomas. Its mechanism of action involves binding to both CD3 on T-cells and CD20 on B-cells, thereby bringing these cells into close proximity and promoting T-cell-mediated killing of B-cell lymphoma. While Epkinly is still under clinical investigation, it has shown promise in early clinical trials for its potential efficacy in treating relapsed or refractory B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.

In clinical studies, Epkinly has demonstrated an encouraging ORR in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The data from these studies suggest that Epkinly can induce a potent and durable response in a subset of patients, with some achieving complete remission. The safety and efficacy of Epkinly continue to be evaluated in ongoing clinical trials, and it has not yet received FDA approval. As such, the use of Epkinly is currently limited to clinical trial settings until further data can support its approval for wider use in the treatment of lymphoma.